PLEASANTON, Calif. –– IntegenX Inc., a privately held company and leading developer of rapid human DNA identification technology, DNA sequencing library preparation systems, and DNA/RNA ambient temperature stability and storage products, today announced the appointment of Robert A. Schueren as Chief Executive Officer.

Robert A. Schueren has nearly 30 years of commercial and operational experience, and has held leadership positions in life science companies for more than two decades. Most recently, he was Vice President and General Manager, Genomics, for Agilent Technologies. Prior to joining Agilent in 2010, he was the Global Head of Clinical Biomarkers and Operations and Deputy Global Head of Molecular Medicine Labs for Genentech, Inc., a company he joined in 2006. While at Genentech,

Mr. Schueren held increasingly responsible positions including Senior Director, Development Sciences and Director Companion Diagnostics. Prior to Genentech, Mr. Schueren was the Executive Vice President and Chief Operating Officer of Arcturus Bioscience from 2003 to 2006. From 1997 to 2002, Mr. Schueren held leadership positions with Accumetrics. He also held commercial positions with Biosite Diagnostics and Gen-Probe, Inc.

“IntegenX is uniquely positioned to lead the revolution in how rapid DNA is applied—one that will transform law enforcement, intelligence and border control. For the first time, rapid DNA profiles will be included in the arsenal of actionable information used for human identification and to strengthen criminal and terrorist investigations.” said Mr. Schueren. “I am excited to participate in this new revolution and look forward to working with the IntegenX team as we drive the development of the significant new markets rapid DNA creates.”

Stevan Jovanovich, Ph.D., a founder and past President and CEO of IntegenX, will remain with the Company as Chief Technology Officer.

“We are delighted to have Bob join the company. His significant commercial and operations experience at companies such as Agilent and Genentech will prove invaluable as IntegenX commercializes its rapid human DNA identification system,” commented Dr. David Barker, Chairman of the Board of IntegenX. “The board is also very pleased that Stevan will assume the role of Chief Technology Officer, where he will continue to play a critical part in building the success of the

Company.”

About IntegenX Inc.

IntegenX, headquartered in Pleasanton, California, is a leading developer of rapid human DNA identification technology, next-generation sequencing library preparation systems, and DNA/RNA ambient temperature stability and storage products. IntegenX technology platforms are the result of the integration of advanced fluidics, optics, and biochemistry capabilities to produce sample-to-answer products for DNA-based human identity testing and forensics, next generation sequencing, and

biodefense applications. The company’s expertise and extensive intellectual property includes its patented MOVe™ valve technology, patent-pending PrepX™ reagent kits for next generation sequencing library preparation, as well as a portfolio of patented DNA and RNA reagents including GenTegra™ for stabilization and storage of purified DNA and RNA, and GenPlate® for storage of blood samples. For more information, please visit www.integenx.com.